We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New H&E Tissue Staining Solution Sets New Standard in Histopathology

By LabMedica International staff writers
Posted on 07 Dec 2015
Print article
A new hematoxylin and eosin (H&E) staining system provides exceptionally high tissue staining quality and efficiency that enhances patient care as well as lab technician safety.

The new “VENTANA HE 600” staining system from Roche (Basel, Switzerland) delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality. This individual slide staining technology mitigates the risk of specimen cross-contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

Elimination of xylene and alcohol and utilization of ready-to-use reagents reduce technician exposure to harmful chemicals. Workflow is improved by eliminating the need to manually mix reagents and track product expiration dates. The system offers over 400 individual staining protocols and is highly customizable, allowing for laboratory and pathologist preferences and tissue variables.

In a recent global test, over 4,000 slides from laboratories in 12 countries were stained on VENTANA HE 600 and reviewed by 67 pathologists with excellent results. Evaluation of the criteria, including nuclear detail and stain quality and intensity, resulted in a score of 3.7 on a scale of 4.0.

Robert C. Babkowski, MD, the lead pathologist on a recent 4-week beta-test conducted at Stamford Hospital where he reviewed over 1,000 slides, said, “When we compared our current system, the VENTANA HE 600 system is easier to use, the slides are exquisite, and the consistency is solid. The new system provides beautifully stained slides every time and has allowed me, as a working pathologist, to be even more efficient. Because the instrument is so easy to operate, my histo-technologists are now able to focus on other key histology functions.” Stamford Hospital is one of 4 beta-test sites.

“Approximately 80% of a pathologist's diagnostic report comes from the H&E stain. The VENTANA HE 600 system will help change the standard of care for laboratories, pathologists and, most importantly, cancer patients, who rely heavily on the H&E test,” said Roland Diggelmann, COO, Roche Diagnostics Division, “The system reflects Roche’s commitment to delivering innovation that meets the labs’ needs of today and tomorrow through meaningful advancements in staining quality, patient and laboratory safety, and workflow.”

Related Links:


Platinum Supplier
Automatic Nucleic Acid Extractor
GeneFlex 16n
3 Part Diff Auto Hematology Analyzer

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.